key: cord-0914889-7kpf4i3f
authors: Ferrari, Alessandro; Cassaniti, Irene; Sammartino, Josè Camilla; Mortellaro, Cristina; Del Fante, Claudia; De Vitis, Simona; Barone, Eugenio; Troletti, Daniela; Prati, Federica; Baldanti, Fausto; Percivalle, Elena; Cesare, Perotti
title: SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment
date: 2022-02-16
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2022.103398
sha: b351d115a93acd8b2577ca98b9526b5f5624927e
doc_id: 914889
cord_uid: 7kpf4i3f

BACKGROUND: Test the ability of Mirasol Pathogen Reduction Technology (PRT, Terumo BCT, Lakewood Co, USA) treatment with riboflavin and ultraviolet light (R + UV) in reducing SARS-CoV-2 infectivity while maintaining blood product quality. MATERIAL AND METHODS: SARS-CoV-2 strains were isolated and titrated to prepare cell free virus for plasma units infection. The units were then under treatment with Mirasol PRT. The infectious titers were determined before and after treatment with an in house microtitration assay on Vero E6 cells. Thirty-six plasma pool bags underwent PRT treatment. RESULTS: In all the experiments, the measured titer following riboflavin and UV treatment was below the limit of detection of microtitration assay for all the different SARS-CoV-2 strains. Despite the high copies number detected by RT-PCR for each viral strain after treatment, viruses were completely inactivated and not able to infect VERO E6 cells. CONCLUSION: Riboflavin and UV light treatment effectively reduced the virus titers of human plasma to the limit of detection in tissue culture, regardless of the strain. These data suggest that pathogen reduction in blood products highlight the safety of CP therapy procedures for critically ill COVID-19 patients, while maintaining blood product quality.

SARS-CoV-2 strains were isolated and titrated to prepare cell free virus for plasma units infection.

The units were then under treatment with Mirasol PRT. The infectious titers were determined before and after treatment with an in house microtitration assay on Vero E6 cells. Thirty-six plasma pool bags underwent PRT treatment.

In all the experiments, the measured titer following riboflavin and UV treatment was below the limit of detection of microtitration assay for all the different SARS-CoV-2 strains. Despite the high copies number detected by RT-PCR for each viral strain after treatment, viruses were completely inactivated and not able to infect VERO E6 cells.

Riboflavin and UV light treatment effectively reduced the virus titers of human plasma to the limit of detection in tissue culture, regardless of the strain. These data suggest that pathogen reduction in blood products highlight the safety of CP therapy procedures for critically ill COVID-19 patients, while maintaining blood product quality.

Passive immunotherapy with convalescent plasma (CP) from recovered subjects is an historic therapeutic tool widely used and a pillar of basic immunology. 1 Indeed, the use of immunoglobulins in the prophylaxis and treatment of viral infections is an irreplaceable tool for the post-exposure prevention of several viral infections like VZ and rabies since long time. 2 When a new infectious J o u r n a l P r e -p r o o f agent appears passive immunotherapy, is the only weapon available to solve public health emergency.

Recently, therapy with convalescent plasma was applied in Western Africa Ebola (2013-2016) and MERS epidemic, (2014 MERS epidemic, ( -2015 . 3 During the SARS-CoV-1 epidemic caused by a Coronavirus, a 23 % reduction in mortality was reached when convalescent plasma was administered at the early stages of disease. 4 Furthermore, the high levels of safety of plasma therapy was confirmed with the daily transfusion practice of plasma products. 5 At the beginning of COVID-19 pandemic, experts debated whether asymptomatic transmission was possible due to the findings of viral RNA in multiple samples tested (including blood), raising considerable concern regarding the safety of convalescent plasma. 6 Viremia was found in 15% of patients from Wuhan, China, with a median PCR cycle threshold of 35.1 suggesting a very low RNA copies number. 7 Several reports found viremia in asymptomatic patients, posing a potential risk in blood donation due to the possibility to escape current health screening performed at the time of donation. Starting from March 2020 until now, in response to the outbreak of the SARS-CoV-2 pandemic, convalescent plasma (CP) has been used for the treatment of severe COVID -19 patients 8 due to the lack of an established therapeutic strategy.

Pathogen reduction systems (PRS) have been also widely implemented to increase the safety of COVID-19 CP, considering that most CP donors have no donation history and thus their donations should be considered at higher infectious risk. The Mirasol Pathogen Reduction Technology (PRT) System (Terumo BCT, Lakewood Co, USA) combines the use of a UV light source and riboflavin (vitamin B2) loading to an irreversible damage to nucleic acids. This system inactivates viruses, bacteria, parasites and white cells, while red blood cells, platelets and plasma proteins are preserved.

Our hospital was the first in Italy to use CP for the treatment of critical COVID-19 patients 9,10 during the first pandemic wave in March 2020. In compliance with the recommendations of National authorithy (Centro Nazionale Sangue) we adopted the Mirasol PRT technology to inactivate CP produced at Tranfusion Service. In the present experimental study, we used infectivity assays to 

Pooled plasma derived from blood donors was divided in 36 equal volume into illumination bags (Mirasol Illumination Bag, Terumo BCT, Lakewood, CO). Riboflavin solution for virus inactivation (35ml) and heparin (Epsoclar, 2500 unit in 0,5mL, Pfizer NY, US) were added to each bag (230 ml total final volume) to avoid plasma coagulation during microtitration assay. An aliquot of plasma sample was removed from each bag and tested for the presence of specific SARS-CoV-2 IgG and neutralizing antibodies (NT-Abs). In addition, a specific real-time RT-PCRs targeting RNAdependent RNA polymerase and ORF8 genes was used to detect presence of SARS-CoV-2. In each plasma bag 200 TCID50 of virus (6 bags respectively for each strain) was added, according to stock titer. Plasma bags were placed into the Mirasol Illuminator for UV inactivation that consists of exposure to 6.24 J/mL UV light for an average time of 10 minutes, according to the manufacturer guidelines (https://www.terumobct.com/mirasol). A pre-and post-treatment sample was obtained for viral titer determination with in-house microtitration assay.

Titration of SARS-CoV2 variants after treatment were defined according to reported protocol. 12 Briefly, 50 μl of plasma sample from each pool bag were diluted in 50 μl (1:2) J o u r n a l P r e -p r o o f

When, in the post treatment samples, no virus was detected in the lowest dilution, the limit of detection for the assay was reached. 14 All values at the limit of detectability of our test were considered less than or equal to the calculated theoretical detection limit. LOD (limit of detection) and log reduction was calculated using the following equations:

Log Reduction = Log (Starting Titer) -Log (Final Titer) N stands for the number of replicas tested at the lowest dilution per sample; V is the volume used for viral titration (volume inoculated/ well in mL). No cytotoxicity occurred at the lowest dilution.

Plasma samples were analyzed using a chemiluminescent immunoassay (CLIA) (LIAISON® SARS-CoV-2 S1/S2 IgG; DiaSorin, Saluggia (VC), Italy) for the quantitative characterization of SARS-CoV-2 anti-S1 and anti-S2 IgG antibodies, according to the manufacturer's instructions. Results were given as AU/mL and a cut-off of 15 AU/mL was considered for definition of positive samples. Results ranging from 12 to 15 AU/mL were considered borderline or weak positive and IgG titres <12 AU/mL were given as a negative result.

For SARS-CoV-2 neutralizing antibodies a titer <1:10 was defined as negative whereas a titer > 1:10 was considered positive. 12 

All analyses reported including descriptive statistics for pathogen reduction were performed using GraphPad Prism software (version 5; GraphPad Software Inc., La Jolla, CA), including mean, standard deviation, coefficient of variation (CV) and numbers of samples analyzed (N).

Thirty-six (N= 36) PF24 pooled plasma units were evaluated using Mirasol PRT system against SARS-CoV-2 and its variants of concern. In order to exclude prior virus neutralization by immune components in the plasma products, we performed a quantitative SARS-CoV-2 S1/S2 IgG and NT-Abs detection that tested negative. Moreover, the investigation by a SARS-CoV-2 specific real-time RT-PCRs for the presence of viral genome in plasma bags before inoculation of the different variants, was negative.

The data collected are shown in Table 1 . The in vitro microtitration assay demonstrated that the pathogen reduction treatment of plasma bags inoculated with SARS-CoV-2 was able to reduce infectious titer to the limit of detection by ≥ 1,21 log for Italian, ≥ 1,13 log for Chinese, ≥ 0,48 log for Alpha, ≥ 0,13 log for Gamma, ≥ 1,22 log for Beta and ≥ 0,59 log for Delta strain. Indeed all thirtysix treated units were reduced to the limit of detection (≤ 1 log10). All samples were tested immediately before and after Mirasol treatment. Furthermore, we tried to isolate the viral strains after treatment, inoculating plasma samples on VERO E6. Despite the high copies number detected by RT-PCR for each viral strain (Table 2) after treatment, viruses were completely inactivated and not able to infect VERO E6 cells (Table 3) .

Convalescent plasma, a source of anti-SARS-CoV-2 antibodies, has been widely used as a treatment for COVID-19 during the present pandemic. The safe use of CP depends mainly on the accuracy in donor screening for transmitted transfusion diseases, potentially harmful for the recipient, considering that many CP donors could be first time donors. 15 

The Mirasol PRT treatment of CP is a safe method that significantly reduces the risk of possible transmitted transfusion infections and, importantly, does not impair plasma quality (e.g.:antibody function 16 ). In the study by Keil et al, the Mirasol PRT system significantly reduced the load of viral agents tested in plasma and platelet products 17 . This method provides a proactive layer of blood safety through its broad-based effectiveness against a wide range of known pathogens.

The European Center for Disease Prevention and Control (ECDC) suggests a precautionary deferral from blood donation for 21 days after any possible exposure for confirmed COVID-19 patients 18 .

Despite SARS-CoV-2 virus was detected at very low levels in blood products 19 and there is no evidence of transfusion transmission at this time, the theoretical and potential risk of SARS-CoV-2 and their variants of concern to be transmitted through transfusion is unknown. Recently Shawn et al. Table 2 . Quantification cycles of SARS-CoV-2 variants is reported as a quantification cycle (CQ) in six pooled plasma bags, analysed post pathogen reduction treatment (PRT). Table 3 . Viral genome detected in pooled plasma after pathogen reduction treatment (PRT) is not able to infect VERO E6 cells. At 120 hours post incubation with VERO E6 cells, plates were scored and showed no cytopathic effect (CPE) due to inactivation of the viral genome.

Convalescent plasma: new evidence for an old therapeutic tool

Uses of immune globulins in the prophylaxis and treatment of viral infections

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression

Coronavirus Disease 2019: Coronaviruses and Blood Safety

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations

Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol

Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19

Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06

Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light

The red blood cell storage lesion: the end of the beginning

Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro

Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment

Low risk of SARS-CoV-2 in blood transfusion

Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment

Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment